SCHEMBL13922018

SCHEMBL13922018

O=S(=O)(OCC1CCN(S(=O)(=O)c2ccccc2)CC1)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
PKM P14618 2/20 0.58
GAA P10253 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
L3MBTL1 Q9Y468 1/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
POLB P06746 1/20 0.50
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3880694 0.85 HTR2A (0.55) ALDH1A1PKMGAAKDM4EMEN1
SCHEMBL3868079 0.85 ALDH1A1 (0.58) ALDH1A1PKMGAAKDM4EMEN1
SCHEMBL6556991 0.82 GBA1 (0.43) ALDH1A1KDM4EMEN1KMT2A
SCHEMBL8885165 0.79 ALDH1A1 (0.63) ALDH1A1PKMGAAKDM4EMEN1
SCHEMBL13888771 0.79 ALDH1A1 (0.63) ALDH1A1PKMGAAKDM4EMEN1
SCHEMBL8223285 0.79 ALDH1A1 (0.63) ALDH1A1PKMGAAKDM4EMEN1
SCHEMBL14470092 0.78 MEN1 (0.81) ALDH1A1PKMGAAMEN1KMT2A
SCHEMBL21541890 0.77 SLC6A2 (0.47) ALDH1A1PKMGAAPOLBNPC1
SCHEMBL13152700 0.76 ALDH1A1 (0.60) ALDH1A1PKMGAAKDM4EMEN1
SCHEMBL9217317 0.76 HTR2A (0.55) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491727-B2 Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches EPIX DELAWARE, INC. (US) 2009-02-17 US disclosed
US-7488731-B2 Arylpiperazinyl compounds EPIX DELAWARE, INC. (US) 2009-02-10 US disclosed
US-20080027066-A1 Arylpiperazinyl Compounds EPIX DELAWARE, INC. 2008-01-31 US disclosed
US-20070004742-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027066-A1 Arylpiperazinyl Compounds HTR5A, HTR1A, HTR2A ALDH1A1 346/4885PKM 2188/4885GAA 1163/4885
US-20070004742-A1 Arylpiperazinyl compounds HTR5A, HTR1A, HTR2A ALDH1A1 346/4885PKM 2188/4885GAA 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.